Breaking News

Affinia Therapeutics, Forge Biologics Enter AAV cGMP Mfg. Pact

Forge will provide tech transfer services, process and analytical development, toxicology, and cGMP manufacturing services to Affinia.

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Affinia Therapeutics, a gene therapy company with a pipeline of adeno-associated virus (AAV) gene therapies for cardiovascular and neurological diseases, and Forge Biologics, a manufacturer of genetic medicines, entered an agreement to tech transfer and manufacture clinical trial material under cGMP to help advance Affinia’s pipeline of development candidates into clinical trials.    The scope includes Affinia’s investigational medicine program, AFTX-201 for BAG3 dilated cardiomyopathy, a deva...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters